Publication | Closed Access

Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer

UrologyRadiation TherapyMedicineRadionuclide TherapyBone-targeted Radiometabolic TherapyRadiopharmaceutical TherapyClinical BenefitCancer TreatmentOncologyRadiation OncologyNuclear MedicineRadiologyHealth Sciences